Skip to main content

Table 3 Associated Risk Factors for the presence of BK Viruria and/or Viremia in children with SLE at the time of enrollment

From: BK viruria and viremia in children with systemic lupus erythematosus

Clinical history Presence of Bk viruria or viremia (N = 12) Absence of BK viruria or viremia (N = 20) P-value
  Median Median  
Age 15 16 0.08
Female 9 17 0.65
Male 3 3
Race    0.79
Caucasian 4 8
African American 3 6
Other 5 6
SLE WHO Class    0.75
I 2 2
II 1 1
III 0 1
III/IV 1 0
IV 3 8
V 2 2
No renal biopsy 3 6
Duration of SLE 21 21 0.89
Laboratory findings
Serum creatinine 0.61 0.66 0.33
Hematuria 1 2 1.0
Proteinuria 2 4 1.0
Hemoglobin 12.45 12.25 0.56
Platelet count 269.5 243 0.77
WBC Count 5.05 5.95 0.89
C3 106 113 0.77
C4 18 19 0.88
CD3 982 1087 0.44
CD19 0 0 0.23
IGG 796 866 0.80
IGA 86 143 0.21
IGM 30 29 0.88
Medication history    
Exposure to any biologic a 11 16 0.62
1 Biologic 10 13
2 Biologics 0 2
3 OR more biologics 1 1
Exposure to IVIG 5 6 0.70
Exposure to hydroxychloroquine 12 9 0.0016 b
Exposure to MMF 9 17 0.65
Exposure to cyclophosphamide 3 11 0.15
Exposure to rituximab 10 15 0.68
Exposure to steroids 12 20 1.0
  1. N number of patients
  2. a Two biologics (Rituximab and Tocilizumab) were given simultaneously in only one patient (patient # 5)
  3. b Statistically significant p-value